Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
LivaNova PLC - Ordinary Shares
(NQ:
LIVN
)
66.21
+8.62 (+14.97%)
Streaming Delayed Price
Updated: 11:23 AM EDT, May 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about LivaNova PLC - Ordinary Shares
< Previous
1
2
3
4
Next >
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Today 6:00 EDT
From
LivaNova PLC
Via
Business Wire
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
April 20, 2026
From
LivaNova PLC
Via
Business Wire
LivaNova to Announce First-Quarter 2026 Results
March 25, 2026
From
LivaNova PLC
Via
Business Wire
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
March 19, 2026
From
LivaNova PLC
Via
Business Wire
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
February 25, 2026
From
LivaNova PLC
Via
Business Wire
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
January 20, 2026
From
LivaNova PLC
Via
Business Wire
LivaNova to Present at J.P. Morgan Healthcare Conference in January
December 23, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
December 03, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
December 02, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Present at Piper Sandler Healthcare Conference in December
November 25, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
November 24, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
November 12, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
November 05, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Present at Wolfe Research Healthcare Conference in November
October 23, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Announce Third-Quarter 2025 Results
October 08, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
October 07, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Appoints Donald Zurbay as a New Director
September 04, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Host Investor Day on November 12, 2025
August 25, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
August 22, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Launches Essenz Perfusion System in China
August 18, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
August 06, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Announce Second-Quarter 2025 Results
July 09, 2025
From
LivaNova PLC
Via
Business Wire
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
June 05, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
June 05, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
June 04, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Present at the Jefferies Global Healthcare Conference
May 15, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
May 07, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
May 07, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova to Announce First-Quarter 2025 Results
March 26, 2025
From
LivaNova PLC
Via
Business Wire
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
February 25, 2025
From
LivaNova PLC
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
